Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Pharma & Biotech
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Pharma & Biotech
Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.
Pharma & Biotech
Can Sarepta’s ELEVIDYS redefine Duchenne therapy? Inside the 3-year EMBARK data
Sarepta’s gene therapy ELEVIDYS shows 3-year durability in Duchenne muscular dystrophy. Find out what it means for patients, payers, and global rollout.
Pharma & Biotech
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor